The Resurgence of the Pulmonary Autograft
For young and middle-aged adults requiring aortic valve replacement (AVR), the choice of prosthesis remains a complex clinical dilemma. While mechanical valves offer long-term durability, they necessitate lifelong anticoagulation with its attendant bleeding risks. Conversely, bioprosthetic valves avoid anticoagulation but are prone to structural valve deterioration, particularly in younger, active patients. In this context, the Ross procedure—the replacement of the diseased aortic valve with the patient’s own pulmonary autograft—has seen a significant resurgence.
Originally described by Donald Ross in 1967, the procedure offers several theoretical and clinical advantages: superior hemodynamics, the potential for autograft growth, and the absence of anticoagulation requirements. However, the technical complexity of the procedure, involving a double-valve operation and coronary artery reimplantation, has historically limited its adoption to specialized centers. A new study by Mazine et al., published in the Journal of the American College of Cardiology, provides a timely and critical assessment of how this procedure is currently utilized in North America and how surgical experience directly influences patient survival.
